Sarepta Therapeutics (FRA:AB3A) Asset Impairment Charge : €0 Mil (TTM As of Dec. 2023)

View and export this data going back to 1997. Start your Free Trial

What is Sarepta Therapeutics Asset Impairment Charge?

Sarepta Therapeutics's Asset Impairment Charge for the three months ended in Dec. 2023 was €0 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2023 was €0 Mil.

Sarepta Therapeutics Asset Impairment Charge Historical Data

The historical data trend for Sarepta Therapeutics's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sarepta Therapeutics Asset Impairment Charge Chart

Sarepta Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Asset Impairment Charge

Get a 7-Day Free Trial

3.97

2.43

27.80

Sarepta Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Asset Impairment Charge	Get a 7-Day Free Trial															-	-	-	-	-

Sarepta Therapeutics Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0 Mil.

Sarepta Therapeutics Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Sarepta Therapeutics's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Sarepta Therapeutics (FRA:AB3A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sarepta Therapeutics Inc (FRA:AB3A) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

SRPT:USA AB3A:Germany S1RP34:Brazil

Address

215 First Street, Suite 415, Cambridge, MA, USA, 02142

Website

https://www.sarepta.com

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development.

Sarepta Therapeutics (FRA:AB3A) Headlines

No Headlines